Anthropic buys biotech startup Coefficient Bio in $400M deal
Anthropic's $400M acquisition of a drug-discovery AI startup isn't a pivot — it's a doubling-down. For health comms teams evaluating Claude as an enterprise tool, this changes the vendor relationship. Anthropic is now a pharma player.
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
The life sciences angle: the deal covers drug opportunity identification and clinical regulatory strategy. The implication for health comms professionals building on Claude's platform is that the roadmap is now explicitly pharma-shaped.
That's it for this edition. Back next week.
— Ned